Digital Health Canada

Canada AI in Clinical Trials Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Canada AI in Clinical Trials Market Industry Trends and Forecast to 2034: Segmented by (Application, Phase, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Canada · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $125.6 Mn Placeholder estimate
Estimate 2025 $155.3 Mn 7.2% of the global market
Projected 2034 $1.05 Bn 578.2% Adds $897.9 Mn over 9 forecast years
CAGR 2025–2034 23.7% Faster than 77% of 100 Digital Health markets here
Key players 5 Companies profiled
  • Canada is 7.21% of the global market.
  • In North America, the largest is US at $1.00 Bn.
  • Fastest growing: Canada (this report) at 23.7% a year.
  • Canada ranks 2nd of 2 by size in North America.

Market size projection

Canada

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$897.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
AI in Clinical Trials Market market size by year, Canada
YearMarket sizeChange that yearSince 2025
2024 (estimate) $125.6 Mn — —
2025 (base) $155.3 Mn +$29.8 Mn —
2026 (forecast) $192.1 Mn +$36.8 Mn +23.7%
2027 (forecast) $237.7 Mn +$45.5 Mn +53%
2028 (forecast) $294.0 Mn +$56.3 Mn +89.3%
2029 (forecast) $363.7 Mn +$69.7 Mn +134.1%
2030 (forecast) $449.8 Mn +$86.2 Mn +189.6%
2031 (forecast) $556.4 Mn +$106.6 Mn +258.3%
2032 (forecast) $688.3 Mn +$131.9 Mn +343.2%
2033 (forecast) $851.5 Mn +$163.1 Mn +448.2%
2034 (forecast) $1.05 Bn +$201.8 Mn +578.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Canada AI in Clinical Trials Market Analysis at a glance
Market size, 2025$155.3 Mn placeholder estimate
Forecast, 2034$1.05 Bn placeholder estimate
Growth (CAGR), 2025–203423.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, phase and end user (see all)
Key playersIQVIA, Medidata (Dassault Systemes), Unlearn.AI, Deep 6 AI, Saama Technologies (see all)
Regulator in CanadaHealth CanadaSource: Health Canada. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Canada AI in Clinical Trials Market Analysis Executive Summary

AI in clinical trials helps design studies, find suitable patients, choose sites and analyse results faster.

Key segments of the AI in Clinical Trials market include application (Patient Recruitment, Trial Design and Site Selection) and phase (Phase I, Phase II and Phase III).

Bar chart: Canada AI in Clinical Trials market size, 2024–2034, placeholder estimates. $125.6 Mn in 2024, $155.3 Mn in 2025 and $1.05 Bn in 2034, 23.7% CAGR.
Canada AI in Clinical Trials market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Canada AI in Clinical Trials Market Dynamics

Market Growth Drivers

Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Clinical Trials market. Health systems are moving from pilots to wider use.

Opportunity

Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Clinical Trials market strong growth, including in emerging health systems.

Market Restraints

Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Clinical Trials market.

Competitive Landscape for AI in Clinical Trials Market in Canada

The AI in Clinical Trials market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AI in Clinical Trials Market in Canada

AI in Clinical Trials in Canada: rules and payment

Software that meets the definition of a medical device needs a Health Canada licence, based on its risk class.⁠[1] Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services.⁠[2]

[1] Health Canada. Checked 14 Nov 2026.

[2] Health Canada. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Rules on software as a medical device, data privacy (such as HIPAA and GDPR) and telehealth reimbursement shape the AI in Clinical Trials market. Government digital health programs in Canada are speeding up adoption.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AI in Clinical Trials right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AI in Clinical Trials in context

Canada compared

  • Health spending per person: 6,378 US$ per person (2024). World: 1,317 US$ per person (2023).[1]
  • Doctors: 2.82 per 1,000 people (2023). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 20.3% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the AI in Clinical Trials market in Canada?
Placeholder estimate: about $155.3 Mn in 2025, rising to about $1.05 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AI in Clinical Trials market in Canada growing?
Placeholder estimate: about 23.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AI in Clinical Trials market report cover?
The report splits the market by application (Patient Recruitment, Trial Design, Site Selection, Data Analysis), phase (Phase I, Phase II, Phase III) and end user (Healthcare Providers, Patients, Payers, Pharmaceutical Companies).
Who are the key players in the AI in Clinical Trials market?
Key players include IQVIA, Medidata (Dassault Systemes), Unlearn.AI, Deep 6 AI and Saama Technologies.
What is driving the AI in Clinical Trials market?
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Clinical Trials market. Health systems are moving from pilots to wider use.
Who regulates AI in Clinical Trials in Canada?
Software that meets the definition of a medical device needs a Health Canada licence, based on its risk class. Source: Health Canada. Checked 14 Nov 2026.
How is healthcare paid for in Canada?
Each province and territory runs public health insurance under the Canada Health Act, which covers medically necessary hospital and doctor services. Source: Health Canada. Checked 14 Nov 2026.
How much research is published on AI in Clinical Trials?
PubMed lists 739 papers on AI in Clinical Trials added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Digital Health reports in Canada

See all

Related on artificial intelligence and clinical trials

See the topic